Associated Papers
Evaluation of the Idylla IDH1-2 Mutation Assay for the Detection of IDH Variants in Solid Tumors and Hematological Malignancies.
Gilson P et al.
International Journal of Molecular Sciences, 2026
Oligoastrocytoma: The Vanishing Entity With True Dual Genotype, a Report, its Molecular Profiles and Review of Literature.
Das S et al.
International Journal of Surgical Pathology, 2025
Association of Klotho Gene Polymorphism and Serum Level of α Klotho Protein with Different Tumor Grades, Overall Survival and Cytokine Profile in Glioma Patients.
Zsemlye E et al.
International Journal of Molecular Sciences, 2025
Tumor DNA from tumor in situ fluid was used to track evolution of glioma under first-line treatment.
Yu J et al.
Frontiers in Oncology, 2025
Genetic mutation patterns among glioblastoma patients in the Taiwanese population - insights from a single institution retrospective study.
Huang YF et al.
Cancer Gene Therapy, 2024
Evaluation of the rapid Idylla IDH1-2 mutation assay in FFPE glioma samples.
Solomon JP et al.
Diagnostic Pathology, 2024
Isocitrate Dehydrogenase 1 and 2 Mutations in Pediatric Neuroblastoma Patients.
Leventoglu E et al.
Medeniyet Medical Journal, 2023
Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation.
Bill M et al.
Blood Advances, 2023
Mitochondrial DNA Changes in Genes of Respiratory Complexes III, IV and V Could Be Related to Brain Tumours in Humans.
Kozakiewicz P et al.
International Journal of Molecular Sciences, 2022
Comprehensive analysis of genetic factors predicting overall survival in Myelodysplastic syndromes.
Maurya N et al.
Scientific Reports, 2022
Additional mutations in IDH1/2-mutated patients with acute myeloid leukemia.
Lu J et al.
International Journal of Laboratory Hematology, 2021
Favorable role of IDH1/2 mutations aided with MGMT promoter gene methylation in the outcome of patients with malignant glioma.
Pandith AA et al.
Future Science Oa, 2020
EGFRvIII expression and isocitrate dehydrogenase mutations in patients with glioma.
Taher MM et al.
Oncology Letters, 2020
Current biomarker-associated procedures of cancer modeling-a reference in the context of IDH1 mutant glioma.
Mehrjardi NZ et al.
Cell Death & Disease, 2020
Correlation between IDH, ATRX, and TERT promoter mutations in glioma.
Ohba S et al.
Brain Tumor Pathology, 2020
Next-Generation Sequencing Improves Diagnosis, Prognosis and Clinical Management of Myeloid Neoplasms.
Carbonell D et al.
Cancers, 2019
Qualitative and Quantitative Analysis of IDH1 Mutation in Progressive Gliomas by Allele-Specific qPCR and Western Blot Analysis.
Perrech M et al.
Technology in Cancer Research & Treatment, 2019
Detection Of Mutations In The Isocitrate Dehydrogenase Genes (IDH1/IDH2) Using castPCRTM In Patients With AML And Their Clinical Impact In Mexico City.
Olarte I et al.
Oncotargets and Therapy, 2019
Advances in sarcoma gene mutations and therapeutic targets.
Gao P et al.
Cancer Treatment Reviews, 2018
Non-canonical IDH1 and IDH2 mutations: a clonal and relevant event in an Italian cohort of gliomas classified according to the 2016 World Health Organization (WHO) criteria.
Visani M et al.
Journal of Neuro-oncology, 2017
Somatic mutations of isocitrate dehydrogenases 1 and 2 are prognostic and follow-up markers in patients with acute myeloid leukaemia with normal karyotype.
Virijevic M et al.
Radiology and Oncology, 2016
Biological Significance of Mutant Isocitrate Dehydrogenase 1 and 2 in Gliomagenesis.
Ohba S et al.
Neurologia Medico-chirurgica, 2016
TERT promoter mutations and telomere length in adult malignant gliomas and recurrences.
Heidenreich B et al.
Oncotarget, 2015
Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients.
Mukasa A et al.
Cancer Science, 2012
Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2.
Amary MF et al.
Nature Genetics, 2011
IDH1 and IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia but rare in other types of hematological disorders.
Zou Y et al.
Biochemical and Biophysical Research Communications, 2010
IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
Marcucci G et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2010
IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors.
Bleeker FE et al.
Human Mutation, 2009
An integrated genomic analysis of human glioblastoma multiforme.
Parsons DW et al.
Science (new York, N.y.), 2008